127 related articles for article (PubMed ID: 36310006)
1. Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice.
Reinacher-Schick A; Arnold D; Venerito M; Goekkurt E; Kraeft AL; Seufferlein T
Oncol Res Treat; 2022; 45(12):752-763. PubMed ID: 36310006
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey.
Orsi G; Di Marco M; Cavaliere A; Niger M; Bozzarelli S; Giordano G; Noventa S; Rapposelli IG; Garajova I; Tortora G; Rodriquenz MG; Bittoni A; Penzo E; De Lorenzo S; Peretti U; Paratore C; Bernardini I; Mosconi S; Spallanzani A; Macchini M; Tamburini E; Bencardino K; Giommoni E; Scartozzi M; Forti L; Valente MM; Militello AM; Cascinu S; Milella M; Reni M
ESMO Open; 2021 Oct; 6(5):100238. PubMed ID: 34392104
[TBL] [Abstract][Full Text] [Related]
3. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
4. Treatment landscape of metastatic pancreatic cancer.
De Dosso S; Siebenhüner AR; Winder T; Meisel A; Fritsch R; Astaras C; Szturz P; Borner M
Cancer Treat Rev; 2021 May; 96():102180. PubMed ID: 33812339
[TBL] [Abstract][Full Text] [Related]
5. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
6. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
7. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
8. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
Orsi G; Cavaliere A; Tortora G; Lonardi S; Macchini M; Di Marco M; Giordano G; Vasile E; Scartozzi M; Bozzarelli S; Noventa S; Rodriquenz MG; Militello AM; Rapposelli IG; Garajova I; De Lorenzo S; Merelli B; Bittoni A; Salvatore L; Procaccio L; Paratore C; Spallanzani A; Peretti U; Niger M; Giommoni E; Bernardini I; Tamburini E; Bernardino K; Forti L; Valente MM; Cascinu S; Milella M; Reni M
Br J Cancer; 2023 Mar; 128(5):877-885. PubMed ID: 36482190
[TBL] [Abstract][Full Text] [Related]
9. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
[TBL] [Abstract][Full Text] [Related]
10. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
11. Surgery After Response to Chemotherapy for Locally Advanced Pancreatic Ductal Adenocarcinoma: A Guide for Management.
Fong ZV; Ferrone CR
J Natl Compr Canc Netw; 2021 Apr; 19(4):459-467. PubMed ID: 33845457
[TBL] [Abstract][Full Text] [Related]
12. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
[TBL] [Abstract][Full Text] [Related]
13. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
15. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
[TBL] [Abstract][Full Text] [Related]
16. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.
Ulusakarya A; Teyar N; Karaboué A; Haydar M; Krimi S; Biondani P; Gumus Y; Chebib A; Almohamad W; Morère JF
Medicine (Baltimore); 2019 Apr; 98(16):e15341. PubMed ID: 31008993
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Cancer: A Review.
Park W; Chawla A; O'Reilly EM
JAMA; 2021 Sep; 326(9):851-862. PubMed ID: 34547082
[TBL] [Abstract][Full Text] [Related]
18. Initial experience with neoadjuvant FOLFIRINOX as first line therapy for locally advanced pancreatic cancer.
Karachaliou GS; Lazarou V; Giannis D; Astras G; Moris D; Petrou A
J BUON; 2020; 25(5):2525-2527. PubMed ID: 33277879
[TBL] [Abstract][Full Text] [Related]
19. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
20. Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain.
Yeh C; Bates SE
Semin Oncol; 2021 Feb; 48(1):34-46. PubMed ID: 33712267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]